Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study

MLA

David Schnell, et al. “Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.” European Journal of Drug Metabolism and Pharmacokinetics, vol. 42, no. 3, July 2016, pp. 461–69. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9cdf6732a9d268c5227adfc3be9caa05&authtype=sso&custid=ns315887.

APA

David Schnell, Dietmar Gansser, Raimund Külzer, Anne Weber, Gudrun Wallenstein, Sven Wind, Sabrina Wiebe, Atef Halabi, & Anja Conrad. (2016). Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study. European Journal of Drug Metabolism and Pharmacokinetics, 42(3), 461–469.

Chicago

David Schnell, Dietmar Gansser, Raimund Külzer, Anne Weber, Gudrun Wallenstein, Sven Wind, Sabrina Wiebe, Atef Halabi, and Anja Conrad. 2016. “Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.” European Journal of Drug Metabolism and Pharmacokinetics 42 (3): 461–69. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....9cdf6732a9d268c5227adfc3be9caa05&authtype=sso&custid=ns315887.